You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion supports the World Federation Of Hemophilia Virtual Summit 2020

The company reaffirms its commitment to the patient community during the COVID-19 epidemic

read more 

CORPORATE

Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel

The two companies are now working to expand the Clinical Development Program to the US

read more 

EVENTS

Kedrion Biopharma supports the 2020 Primary Immunodeficiency Week

The company stands alongside the global PI community

read more 
  1. Kedrion - Feature thumbnail

    CORPORATE - 28-12-2016

    Kedrion Biopharma strengthens its presence in Russia

    Memorandum of Understanding with Russian pharmaceutical companies for a joint plasma products manufacturing program

    read more 
  2. PLASMA & BIOTHERAPIES - 08-11-2016

    FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin

    Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017

    read more 
  3. FEATURED STORIES - 24-10-2016

    Hemophilia seen through children's eyes: Kedrion teams up with LA Kelley

    Three books of the series My First Factor Creation are now available for free download

    read more 
  4. EVENTS - 17-10-2016

    Kedrion took part in the 17th ESID Meeting with 44 international guests

    The conference focused on new insights into PIDs’ diagnosis and therapies

    read more 

Pages

For more information please contact: pressoffice@kedrion.com